ACB1801 enhances tumor immunogenicity by targeting glycolysis/ferroptosis vulnerability and activating STAT1-signaling to overcome anti-PD-1 resistance in MSS colorectal cancer
Ruize Gao, Kris Van Moer, Coralie Pulido, Anaïs Oudin, Chenxi Li, Margaux Poussard, teresa L Ramos, Diane Murera, Elisabetta Bartolini, Annette Ives, Marine Gerbé de Thoré, Michele Mondini, Éric Deutsch, Guy Berchem, Christian Auclair, Bassam Janji
ACB1801 enhances anti-PD-1 therapy efficacy in MSS CRC by reprogramming the TME through metabolic reprogramming and STAT1 signaling activation.
bioRxiv · Feb 25, 2026 · PreprintCancer Biology